http://hl7.org/fhir/uv/ebm/Composition/399871
type: Composition
node role: treeRoot
id:
  v: 399871
meta:
  version id:
    v: 5
  last updated:
    v: 2025-12-11T20:35:21.032Z
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-report
    l: participant-flow-report
language:
  v: en
text:
  status:
    v: generated
  div:
    v: Generated Narrative: Composition 399871 version: 5; Last updated: 2025-12-11 20:35:21+0000; Language: en Profile: ParticipantFlowReport url: https://fevir.net/resources/Composition/399871 identifier: FEvIR Object Identifier/399871, FEvIR Linking Identifier/NCT03421379-participant-flow-report status: Final type: Participant Flow Report date: 2025-12-11 20:35:21+0000 author: [No author listed.] title: Participant Flow Report for NCT03421379 custodian: Computable Publishing LLC RelatesTos - Type Target[x] * Cite As Participant Flow Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399871. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399871. Computable resource at: https://fevir.net/resources/Composition/399871#json. Generated Narrative: Group #FG000 Profile: ExposureGroup name: NCT03421379 Flow Group Glucagon Nasal Powder/Glucagon Hydrochloride description: A single dose of 3 milligram (mg) glucagon nasal powder was administered intranasally in period 1 then 1 mg single dose intramuscular glucagon hydrochloride solution was administered in period 2. type: Person membership: Enumerated Characteristics - Code Value[x] Exclude * Research Study from which this is a flow group NCT03421379 false Generated Narrative: Group #FG001 Profile: ExposureGroup name: NCT03421379 Flow Group Glucagon Hydrochloride Solution/Glucagon Nasal Powder description: A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM) in period 1 then 3 mg single dose glucagon nasal powder was administered in period 2. type: Person membership: Enumerated Characteristics - Code Value[x] Exclude * Research Study from which this is a flow group NCT03421379 false Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Period-1-group-FG000 Profile: ParticipantFlowEvidence identifier: FEvIR Linking Identifier/NCT…
contained: Group
  id:
    v: FG000
  meta:
    profile:
      v: http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group
      l: exposure-group
  name:
    v: NCT03421379 Flow Group Glucagon Nasal Powder/Glucagon Hydrochloride
  description:
    v: A single dose of 3 milligram (mg) glucagon nasal powder was administered intranasally in period 1 then 1 mg single dose intramuscular glucagon hydrochloride solution was administered in period 2.
  type:
    v: person
  membership:
    v: enumerated
  characteristic:
    code:
      text:
        v: Research Study from which this is a flow group
    value: Reference
      display:
        v: NCT03421379
    exclude:
      v: false
contained: Group
  id:
    v: FG001
  meta:
    profile:
      v: http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group
      l: exposure-group
  name:
    v: NCT03421379 Flow Group Glucagon Hydrochloride Solution/Glucagon Nasal Powder
  description:
    v: A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM) in period 1 then 3 mg single dose glucagon nasal powder was administered in period 2.
  type:
    v: person
  membership:
    v: enumerated
  characteristic:
    code:
      text:
        v: Research Study from which this is a flow group
    value: Reference
      display:
        v: NCT03421379
    exclude:
      v: false
contained: Evidence
  id:
    v: NCT03421379-flow-milestone-0-Period-1-group-FG000
  meta:
    profile:
      v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
      l: participant-flow-evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: NCT03421379-flow-milestone-0-Period-1-group-FG000
    assigner:
      display:
        v: Computable Publishing LLC
  title:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 1
  status:
    v: active
  author:
    name:
      v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
  use context:
    code:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: evidence-communication
      display:
        v: Evidence Communication
    value: CodeableConcept
  variable definition:
    variable role:
      v: population
    observed:
      l: FG000
      reference:
        v: #FG000
      type:
        v: Group
        l: Group
      display:
        v: Glucagon Nasal Powder/Glucagon Hydrochloride
  variable definition:
    variable role:
      v: outcome
    observed:
      display:
        v: STARTED at Period 1
  statistic:
    quantity:
      value:
        v: 34
contained: Evidence
  id:
    v: NCT03421379-flow-milestone-0-Period-1-group-FG001
  meta:
    profile:
      v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
      l: participant-flow-evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: NCT03421379-flow-milestone-0-Period-1-group-FG001
    assigner:
      display:
        v: Computable Publishing LLC
  title:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 1
  status:
    v: active
  author:
    name:
      v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
  use context:
    code:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: evidence-communication
      display:
        v: Evidence Communication
    value: CodeableConcept
  variable definition:
    variable role:
      v: population
    observed:
      l: FG001
      reference:
        v: #FG001
      type:
        v: Group
        l: Group
      display:
        v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
  variable definition:
    variable role:
      v: outcome
    observed:
      display:
        v: STARTED at Period 1
  statistic:
    quantity:
      value:
        v: 41
contained: Evidence
  id:
    v: NCT03421379-flow-milestone-1-Period-1-group-FG000
  meta:
    profile:
      v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
      l: participant-flow-evidence
  identifier:
    type:
      text:
        v: FEvIR Linking Identifier
    system:
      v: https://fevir.net/FLI
      l: FLI
    value:
      v: NCT03421379-flow-milestone-1-Period-1-group-FG000
    assigner:
      display:
        v: Computable Publishing LLC

v: ParticipantFlowEvidence

v: ParticipantFlowEvidence

v: STATO:0000047

v: Count

v: ParticipantFlowEvidence

v: ParticipantFlowEvidence

v: STATO:0000047

v: Count

v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Received at Least One Dose of Study Drug at Period 1

v: active

name:
  v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter

code:
  system:
    v: https://fevir.net/resources/CodeSystem/179423
    l: https://fevir.net/resources/CodeSystem/179423
  code:
    v: evidence-communication
  display:
    v: Evidence Communication
value: CodeableConcept
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: ParticipantFlowEvidence
    display:
      v: ParticipantFlowEvidence

variable role:
  v: population
observed:
  l: FG000
  reference:
    v: #FG000
  type:
    v: Group
    l: Group
  display:
    v: Glucagon Nasal Powder/Glucagon Hydrochloride

variable role:
  v: outcome
observed:
  display:
    v: Received at Least One Dose of Study Drug at Period 1

statistic type:
  coding:
    system:
      v: https://fevir.net/sevco
      l: sevco
    code:
      v: STATO:0000047
    display:
      v: Count
quantity:
  value:
    v: 33

Evidence
id:
  v: NCT03421379-flow-milestone-1-Period-1-group-FG001
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-milestone-1-Period-1-group-FG001
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Received at Least One Dose of Study Drug at Period 1
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG001
    reference:
      v: #FG001
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: Received at Least One Dose of Study Drug at Period 1
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  quantity:
    value:
      v: 39

Evidence
id:
  v: NCT03421379-flow-milestone-2-Period-1-group-FG000
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-milestone-2-Period-1-group-FG000
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 1
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG000
    reference:
      v: #FG000
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Nasal Powder/Glucagon Hydrochloride
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: COMPLETED at Period 1
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  quantity:
    value:
      v: 32

Evidence
id:
  v: NCT03421379-flow-milestone-2-Period-1-group-FG001
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-milestone-2-Period-1-group-FG001
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 1
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG001
    reference:
      v: #FG001
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: COMPLETED at Period 1
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  quantity:
    value:
      v: 37

Evidence
id:
  v: NCT03421379-flow-milestone-3-Period-1-group-FG000
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-milestone-3-Period-1-group-FG000
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 1
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG000
    reference:
      v: #FG000
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Nasal Powder/Glucagon Hydrochloride
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: NOT COMPLETED at Period 1
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  quantity:
    value:
      v: 2

Evidence
id:
  v: NCT03421379-flow-milestone-3-Period-1-group-FG001
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-milestone-3-Period-1-group-FG001
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 1
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG001
    reference:
      v: #FG001
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: NOT COMPLETED at Period 1
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  quantity:
    value:
      v: 4

Evidence
id:
  v: NCT03421379-flow-reason-Period-1-group-FG000
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-reason-Period-1-group-FG000
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Reasons for withdraw at Period 1
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG000
    reference:
      v: #FG000
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Nasal Powder/Glucagon Hydrochloride
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: Reasons for withdraw at Period 1
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  category:
    text:
      v: Withdrawal by Subject
  quantity:
    value:
      v: 0
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  category:
    text:
      v: Physician Decision
  quantity:
    value:
      v: 1
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  category:
    text:
      v: Did not receive treatment
  quantity:
    value:
      v: 1

Evidence
id:
  v: NCT03421379-flow-reason-Period-1-group-FG001
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-reason-Period-1-group-FG001
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Reasons for withdraw at Period 1
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG001
    reference:
      v: #FG001
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: Reasons for withdraw at Period 1
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  category:
    text:
      v: Withdrawal by Subject
  quantity:
    value:
      v: 1
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  category:
    text:
      v: Physician Decision
  quantity:
    value:
      v: 1
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  category:
    text:
      v: Did not receive treatment
  quantity:
    value:
      v: 2

Evidence
id:
  v: NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Washout Period (3 to 14 Days)
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG000
    reference:
      v: #FG000
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Nasal Powder/Glucagon Hydrochloride
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: STARTED at Washout Period (3 to 14 Days)
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  quantity:
    value:
      v: 32

Evidence
id:
  v: NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Washout Period (3 to 14 Days)
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG001
    reference:
      v: #FG001
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: STARTED at Washout Period (3 to 14 Days)
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  quantity:
    value:
      v: 37

Evidence
id:
  v: NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Washout Period (3 to 14 Days)
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG000
    reference:
      v: #FG000
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Nasal Powder/Glucagon Hydrochloride
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: COMPLETED at Washout Period (3 to 14 Days)
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  quantity:
    value:
      v: 32

Evidence
id:
  v: NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Washout Period (3 to 14 Days)
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG001
    reference:
      v: #FG001
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: COMPLETED at Washout Period (3 to 14 Days)
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  quantity:
    value:
      v: 37

Evidence
id:
  v: NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Washout Period (3 to 14 Days)
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG000
    reference:
      v: #FG000
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Nasal Powder/Glucagon Hydrochloride
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: NOT COMPLETED at Washout Period (3 to 14 Days)
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  quantity:
    value:
      v: 0

Evidence
id:
  v: NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Washout Period (3 to 14 Days)
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG001
    reference:
      v: #FG001
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: NOT COMPLETED at Washout Period (3 to 14 Days)
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  quantity:
    value:
      v: 0

Evidence
id:
  v: NCT03421379-flow-milestone-0-Period-2-group-FG000
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-milestone-0-Period-2-group-FG000
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 2
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG000
    reference:
      v: #FG000
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Nasal Powder/Glucagon Hydrochloride
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: STARTED at Period 2
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  quantity:
    value:
      v: 32

Evidence
id:
  v: NCT03421379-flow-milestone-0-Period-2-group-FG001
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-milestone-0-Period-2-group-FG001
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 2
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG001
    reference:
      v: #FG001
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: STARTED at Period 2
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  quantity:
    value:
      v: 37

Evidence
id:
  v: NCT03421379-flow-milestone-1-Period-2-group-FG000
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-milestone-1-Period-2-group-FG000
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 2
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG000
    reference:
      v: #FG000
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Nasal Powder/Glucagon Hydrochloride
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: COMPLETED at Period 2
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  quantity:
    value:
      v: 32

Evidence
id:
  v: NCT03421379-flow-milestone-1-Period-2-group-FG001
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-milestone-1-Period-2-group-FG001
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 2
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG001
    reference:
      v: #FG001
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: COMPLETED at Period 2
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  quantity:
    value:
      v: 37

Evidence
id:
  v: NCT03421379-flow-milestone-2-Period-2-group-FG000
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-milestone-2-Period-2-group-FG000
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 2
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG000
    reference:
      v: #FG000
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Nasal Powder/Glucagon Hydrochloride
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: NOT COMPLETED at Period 2
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  quantity:
    value:
      v: 0

Evidence
id:
  v: NCT03421379-flow-milestone-2-Period-2-group-FG001
meta:
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence
    l: participant-flow-evidence
identifier:
  type:
    text:
      v: FEvIR Linking Identifier
  system:
    v: https://fevir.net/FLI
    l: FLI
  value:
    v: NCT03421379-flow-milestone-2-Period-2-group-FG001
  assigner:
    display:
      v: Computable Publishing LLC
title:
  v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 2
status:
  v: active
author:
  name:
    v: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
use context:
  code:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: evidence-communication
    display:
      v: Evidence Communication
  value: CodeableConcept
    coding:
      system:
        v: https://fevir.net/resources/CodeSystem/179423
        l: https://fevir.net/resources/CodeSystem/179423
      code:
        v: ParticipantFlowEvidence
      display:
        v: ParticipantFlowEvidence
variable definition:
  variable role:
    v: population
  observed:
    l: FG001
    reference:
      v: #FG001
    type:
      v: Group
      l: Group
    display:
      v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder
variable definition:
  variable role:
    v: outcome
  observed:
    display:
      v: NOT COMPLETED at Period 2
statistic:
  statistic type:
    coding:
      system:
        v: https://fevir.net/sevco
        l: sevco
      code:
        v: STATO:0000047
      display:
        v: Count
  quantity:
    value:
      v: 0

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v2-0203
      l: v2-0203
    code:
      v: ACSN
    display:
      v: Accession ID
  text:
    v: FEvIR Object Identifier
system:
  v: https://fevir.net/FOI
  l: FOI
value:
  v: 399871
assigner:
  display:
    v: Computable Publishing LLC

type:
  text:
    v: FEvIR Linking Identifier
system:
  v: https://fevir.net/FLI
  l: FLI
value:
  v: NCT03421379-participant-flow-report
assigner:
  display:
    v: Computable Publishing LLC

v: final

coding:
  system:
    v: https://fevir.net/resources/CodeSystem/179423
    l: https://fevir.net/resources/CodeSystem/179423
  code:
    v: ParticipantFlowReport
  display:
    v: ParticipantFlowReport
text:
  v: Participant Flow Report

v: 2025-12-11T20:35:21.032Z

display:
  v: [No author listed.]

v: Participant Flow Report for NCT03421379

l: http://hl7.org/fhir/uv/ebm/Organization/118079
reference:
  v: Organization/118079
type:
  v: Organization
  l: Organization
display:
  v: Computable Publishing LLC

type:
  v: cite-as
target: Markdown
  v: Participant Flow Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399871. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399871. Computable resource at: https://fevir.net/resources/Composition/399871#json.

title:
  v: Flow PreAssignment Details
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: participant-flow-details
    display:
      v: Participant Flow Details
  text:
    v: FlowPreAssignmentDetails
text:
  status:
    v: generated
  div:
    v: Participants were randomized to receive either nasal glucagon or intramuscular (IM) glucagon in the first period, followed by the alternate treatment in the second period.

title:
  v: Flow Group List
code:
  text:
    v: FlowGroupList
text:
  status:
    v: generated
  div:
    v: Glucagon Nasal Powder/Glucagon Hydrochloride, Glucagon Hydrochloride Solution/Glucagon Nasal Powder
entry:
  l: FG000
  reference:
    v: #FG000
  type:
    v: Group
    l: Group
  display:
    v: Glucagon Nasal Powder/Glucagon Hydrochloride
entry:
  l: FG001
  reference:
    v: #FG001
  type:
    v: Group
    l: Group
  display:
    v: Glucagon Hydrochloride Solution/Glucagon Nasal Powder

title:
  v: STARTED at Period 1
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: results
    display:
      v: Results
  text:
    v: Participant Flow Results
focus:
  display:
    v: STARTED at Period 1
text:
  status:
    v: empty
  div:
    v: [No data.]
entry:
  l: NCT03421379-flow-milestone-0-Period-1-group-FG000
  reference:
    v: #NCT03421379-flow-milestone-0-Period-1-group-FG000
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 1
entry:
  l: NCT03421379-flow-milestone-0-Period-1-group-FG001
  reference:
    v: #NCT03421379-flow-milestone-0-Period-1-group-FG001
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 1

title:
  v: Received at Least One Dose of Study Drug at Period 1
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: results
    display:
      v: Results
  text:
    v: Participant Flow Results
focus:
  display:
    v: Received at Least One Dose of Study Drug at Period 1
text:
  status:
    v: empty
  div:
    v: [No data.]
entry:
  l: NCT03421379-flow-milestone-1-Period-1-group-FG000
  reference:
    v: #NCT03421379-flow-milestone-1-Period-1-group-FG000
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Received at Least One Dose of Study Drug at Period 1
entry:
  l: NCT03421379-flow-milestone-1-Period-1-group-FG001
  reference:
    v: #NCT03421379-flow-milestone-1-Period-1-group-FG001
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Received at Least One Dose of Study Drug at Period 1

title:
  v: COMPLETED at Period 1
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: results
    display:
      v: Results
  text:
    v: Participant Flow Results
focus:
  display:
    v: COMPLETED at Period 1
text:
  status:
    v: empty
  div:
    v: [No data.]
entry:
  l: NCT03421379-flow-milestone-2-Period-1-group-FG000
  reference:
    v: #NCT03421379-flow-milestone-2-Period-1-group-FG000
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 1
entry:
  l: NCT03421379-flow-milestone-2-Period-1-group-FG001
  reference:
    v: #NCT03421379-flow-milestone-2-Period-1-group-FG001
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 1

title:
  v: NOT COMPLETED at Period 1
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: results
    display:
      v: Results
  text:
    v: Participant Flow Results
focus:
  display:
    v: NOT COMPLETED at Period 1
text:
  status:
    v: empty
  div:
    v: [No data.]
entry:
  l: NCT03421379-flow-milestone-3-Period-1-group-FG000
  reference:
    v: #NCT03421379-flow-milestone-3-Period-1-group-FG000
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 1
entry:
  l: NCT03421379-flow-milestone-3-Period-1-group-FG001
  reference:
    v: #NCT03421379-flow-milestone-3-Period-1-group-FG001
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 1

title:
  v: Reasons for withdraw at Period 1
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: results
    display:
      v: Results
  text:
    v: Participant Flow Results
focus:
  display:
    v: Reasons for withdraw at Period 1
text:
  status:
    v: empty
  div:
    v: [No data.]
entry:
  l: NCT03421379-flow-reason-Period-1-group-FG000
  reference:
    v: #NCT03421379-flow-reason-Period-1-group-FG000
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Reasons for withdraw at Period 1
entry:
  l: NCT03421379-flow-reason-Period-1-group-FG001
  reference:
    v: #NCT03421379-flow-reason-Period-1-group-FG001
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Reasons for withdraw at Period 1

title:
  v: STARTED at Washout Period (3 to 14 Days)
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: results
    display:
      v: Results
  text:
    v: Participant Flow Results
focus:
  display:
    v: STARTED at Washout Period (3 to 14 Days)
text:
  status:
    v: empty
  div:
    v: [No data.]
entry:
  l: NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000
  reference:
    v: #NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Washout Period (3 to 14 Days)
entry:
  l: NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001
  reference:
    v: #NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Washout Period (3 to 14 Days)

title:
  v: COMPLETED at Washout Period (3 to 14 Days)
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: results
    display:
      v: Results
  text:
    v: Participant Flow Results
focus:
  display:
    v: COMPLETED at Washout Period (3 to 14 Days)
text:
  status:
    v: empty
  div:
    v: [No data.]
entry:
  l: NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000
  reference:
    v: #NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Washout Period (3 to 14 Days)
entry:
  l: NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001
  reference:
    v: #NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Washout Period (3 to 14 Days)

title:
  v: NOT COMPLETED at Washout Period (3 to 14 Days)
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: results
    display:
      v: Results
  text:
    v: Participant Flow Results
focus:
  display:
    v: NOT COMPLETED at Washout Period (3 to 14 Days)
text:
  status:
    v: empty
  div:
    v: [No data.]
entry:
  l: NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000
  reference:
    v: #NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Washout Period (3 to 14 Days)
entry:
  l: NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001
  reference:
    v: #NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Washout Period (3 to 14 Days)

title:
  v: STARTED at Period 2
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: results
    display:
      v: Results
  text:
    v: Participant Flow Results
focus:
  display:
    v: STARTED at Period 2
text:
  status:
    v: empty
  div:
    v: [No data.]
entry:
  l: NCT03421379-flow-milestone-0-Period-2-group-FG000
  reference:
    v: #NCT03421379-flow-milestone-0-Period-2-group-FG000
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 2
entry:
  l: NCT03421379-flow-milestone-0-Period-2-group-FG001
  reference:
    v: #NCT03421379-flow-milestone-0-Period-2-group-FG001
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 2

title:
  v: COMPLETED at Period 2
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: results
    display:
      v: Results
  text:
    v: Participant Flow Results
focus:
  display:
    v: COMPLETED at Period 2
text:
  status:
    v: empty
  div:
    v: [No data.]
entry:
  l: NCT03421379-flow-milestone-1-Period-2-group-FG000
  reference:
    v: #NCT03421379-flow-milestone-1-Period-2-group-FG000
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 2
entry:
  l: NCT03421379-flow-milestone-1-Period-2-group-FG001
  reference:
    v: #NCT03421379-flow-milestone-1-Period-2-group-FG001
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 2

title:
  v: NOT COMPLETED at Period 2
code:
  coding:
    system:
      v: https://fevir.net/resources/CodeSystem/179423
      l: https://fevir.net/resources/CodeSystem/179423
    code:
      v: results
    display:
      v: Results
  text:
    v: Participant Flow Results
focus:
  display:
    v: NOT COMPLETED at Period 2
text:
  status:
    v: empty
  div:
    v: [No data.]
entry:
  l: NCT03421379-flow-milestone-2-Period-2-group-FG000
  reference:
    v: #NCT03421379-flow-milestone-2-Period-2-group-FG000
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 2
entry:
  l: NCT03421379-flow-milestone-2-Period-2-group-FG001
  reference:
    v: #NCT03421379-flow-milestone-2-Period-2-group-FG001
  type:
    v: Evidence
    l: Evidence
  display:
    v: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 2